FDA Drug Recalls

Recalls / Class II

Class IID-1325-2020

Product

Gaviscon Liquid Antacid Extra Strength, Cool Mint, 12 FL OZ (355 mL) single pack and twin pack, Distributed by: GSK Consumer Healthcare Warren, NJ 07059, NDC 0135-0095-41

Brand name
Gaviscon
Generic name
Aluminum Hydroxide And Magnesium Carbonate
Active ingredients
Aluminum Hydroxide, Magnesium Carbonate
Route
Oral
NDCs
0135-0094, 0135-0095, 0135-0574
FDA application
M001
Affected lot / code info
Lot #: 0A21C1, Exp 12/31/2021; 0A31C1, Exp 12/31/2021; 0B05C1, Exp 12/31/2021; 8J04C1, Exp 7/31/2020; 8L05C1, Exp 9/30/200; 8L13C1 , Exp 10/31/2020; 9A14C1, Exp 12/31/2020; 9A21C1, Exp 12/31/2020; 9B04C1, Exp 12/31/2020; 9B11C1, Exp 1/31/2021; 9C04C1, Exp 1/31/2021; 9C12C1, Exp 2/28/2021; 9C25C1, Exp 2/28/2021; 9D17C1, Exp 3/312021; 9D24C1, Exp 3/312021; 9E01C1, Exp 3/31/2021; 9E10C1, Exp 3/31/2021; 9E21C1, Exp 4/30/2021; 9F11C1, Exp 5/31/2021; 9G15C1, Exp 6/30/2021; 9G30C1, Exp 6/30/2021; 9H06C1, Exp 6/30/2021; 9H12C1, Exp 7/31/2021, 9H2OC1, Exp 7/31/2021; 9H26C1, Exp 7/31/2021; 9J23C1, Exp 8/31/2021; 9J3OC1, Exp 8/31/2021; 9K08C1, Exp 8/31/2021; 9L11C1, Exp 10/31/2021; 9L18C1, Exp 10/31/2021; 9M02C1, Exp 10/31/2021; 9M09C1, Exp 11/30/2021; 9M17C1, Exp 11/30/2021; 19N1587221, Exp 7/31/2020; 19N1743754, Exp 12/31/2020; 19N1948440, Exp 6/30/2021; 19N1958219, Exp 6/30/2021; 20N2019997, Exp 7/31/2021; 20N2026258, Exp 8/31/2021; 20N2057778, Exp 8/31/2021

Why it was recalled

Labeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.

Recalling firm

Firm
Glaxosmithkline Consumer Healthcare Holdings
Manufacturer
Haleon US Holdings LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
184 Liberty Corner Rd, Warren, New Jersey 07059-6796

Distribution

Quantity
1,631,700 bottles & 27,300 Twin-Pack botles
Distribution pattern
U.S.A. Nationwide

Timeline

Recall initiated
2020-05-28
FDA classified
2020-06-18
Posted by FDA
2020-06-24
Terminated
2022-01-24
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1325-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.